FDA Adverse Event Injury Summary report: N

ROCHESTER INTERMITTENT MAGIC3

MDR report key: 4963062 · Received July 31, 2015

Report

Report Number
1018233-2015-00275
Event Type
Injury
Date Received
July 31, 2015
Report Date
July 30, 2015
Manufacturer
ROCHESTER MEDICAL CORP
Product Code
KOD
PMA / PMN Number
K000723
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NJ, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE WAS NOT RETURNED FOR EVALUATION. THE LOT NUMBER IS UNKNOWN THEREFORE THE DEVICE HISTORY RECORD COULD NOT BE REVIEWED. THE INSTRUCTIONS FOR USE STATES THE FOLLOWING: "HOW TO PREPARE AND USE THE MAGIC 3 CATHETER. THE CATHETER IS INTENDED FOR URINARY BLADDER DRAINAGE IN PATIENTS REQUIRING CATHETERIZATION FOR MANAGEMENT OF INCONTINENCE, VOIDING DYSFUNCTION, AND SURGICAL PROCEDURES. THIS IS A SINGLE USE DEVICE. DO NOT REUSE. REUSE OF A SINGLE USE DEVICE INCREASES THE RISK OF CATHETER ACQUIRED URINARY TRACT INFECTIONS. URETHRAL CATHETER FOR UROLOGICAL USE ONLY. DISCARD AFTER USE, DO NOT RESTERILIZE. MADE OF SILICONE ELASTOMER." (B)(4) - THE INFORMATION PROVIDED BY BARD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BARD.

Additional Manufacturer Narrative · 1

INVESTIGATION IS STILL IN PROGRESS. ONCE THE INVESTIGATION IS COMPLETE, A SUPPLEMENTAL REPORT WILL BE FILED.

Description of Event or Problem · 1

IT WAS REPORTED THAT AS A RESULT OF USING THE DEVICE THE PT ALLEGEDLY EXPERIENCED A URINARY TRACT INFECTION, BURNING WHILE URINATING AND ABDOMINAL PAIN IN (B)(6) 2015. IN THE PAST, THE PT WOULD REUSE HER CATHETERS. THE PT WAS PRESCRIBED CIPRO IN (B)(6) 2015 AND CEFALEXIN IN (B)(6) 2015 TO TREAT THE INFECTION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
498919 ROCHESTER INTERMITTENT MAGIC3 KOD ROCHESTER MEDICAL CORP NA NA

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention